Report of Foreign Issuer (6-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2019

Commission File Number: 001-31368

 

 

SANOFI

(Translation of registrant’s name into English)

 

 

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ☐            No  ☒

If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-________

 

 

 

---

In July 2019, Sanofi issued the press releases and the statement attached hereto as Exhibit 99.1, 99.2, 99.3 and 99.4 which are incorporated herein by reference.

Exhibit List

 

Exhibit No.		Description
Exhibit 99.1		Press release dated July 29, 2019: Sanofi delivered solid growth in Q2 2019
Exhibit 99.2		Press release dated July 26, 2019: Sanofi provides update on ZynquistaTM (sotagliflozin) type 2 diabetes Phase 3 program and collaboration with Lexicon
Exhibit 99.3		Press release dated July 26, 2019: Information on the departure conditions of Olivier Brandicourt, Chief Executive Officer
Exhibit 99.4		Product Sales Statement, for the Product Sales Measuring Period Ended June 30, 2019

 

2

---

Exhibit Index

 

Exhibit No.		Description
Exhibit 99.1		Press release dated July 29, 2019: Sanofi delivered solid growth in Q2 2019
Exhibit 99.2		Press release dated July 26, 2019: Sanofi provides update on ZynquistaTM (sotagliflozin) type 2 diabetes Phase 3 program and collaboration with Lexicon
Exhibit 99.3		Press release dated July 26, 2019: Information on the departure conditions of Olivier Brandicourt, Chief Executive Officer
Exhibit 99.4		Product Sales Statement, for the Product Sales Measuring Period Ended June 30, 2019

 

3

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: July 29, 2019						SANOFI
				By		/s/ Alexandra Roger
						Name: Alexandra Roger
						Title:   Head of Securities Law and Capital Markets

 

4